ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

Summary

The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.

Timeline

Start

2022-04-27

Primary completion

2022-09-07

Completion

2022-09-07

Outcome

Outcome not reported

Stopped (Business): “Sponsor undergoing financial hardships - no longer able to support trial; no safety concerns.”

Drugs

Indications